Last updated: September 7, 2026
WTX101, now known as ALXN1840 and commonly identified as bis-choline tetrathiomolybdate, is an investigational oral therapy for Wilson disease. Alexion Pharmaceuticals, an AstraZeneca company, acquired the program through its 2018 purchase of Wilson Therapeutics. The drug is designed to remove excess copper and reduce non-ceruloplasmin-bound copper, a toxic copper fraction associated with organ damage in Wilson disease.
As of the latest publicly reported development information, ALXN1840 had not received FDA approval. Its commercial value depends on regulatory resolution, differentiation from established chelators and zinc therapies, and the ability to secure reimbursement for a rare-disease product. A reasonable long-term global sales range is approximately $300 million to $800 million annually, with upside above $1 billion if the product gains broad first-line use and obtains strong pricing.
What is WTX101 and how does it work?
WTX101 is the former development code for bis-choline tetrathiomolybdate. Alexion later renamed the compound ALXN1840.
The therapy is intended to treat Wilson disease, an inherited disorder caused primarily by pathogenic variants in the ATP7B gene. Defective copper transport causes copper accumulation in the liver, brain and other tissues. Current treatment options include:
- Penicillamine
- Trientine
- Zinc salts
- Liver transplantation for advanced disease
Bis-choline tetrathiomolybdate is designed to bind copper and facilitate its removal. It also targets exchangeable and non-ceruloplasmin-bound copper, which are clinically relevant measures of copper toxicity. This mechanism differs from zinc therapy, which primarily reduces intestinal copper absorption, and from traditional chelators, which rely on urinary copper excretion.
What is the current development status of ALXN1840?
ALXN1840 completed mid- and late-stage clinical development in Wilson disease, including the Phase 3 FoCus study.
| Development item |
Status |
| Former code |
WTX101 |
| Current code |
ALXN1840 |
| Active ingredient |
Bis-choline tetrathiomolybdate |
| Disease |
Wilson disease |
| Route |
Oral |
| Lead developer |
Alexion Pharmaceuticals, AstraZeneca |
| Registration pathway |
Standard rare-disease drug development |
| Phase 3 study |
FoCus |
| FDA approval |
Not approved in the latest publicly available record |
| Commercial status |
No marketed WTX101 product |
| Orange Book listing |
None before FDA approval |
The FoCus study evaluated ALXN1840 against standard-of-care treatment and focused on the reduction of non-ceruloplasmin-bound copper. The program’s clinical rationale is strongest in patients with active copper overload, inadequate control on existing therapy, intolerance to traditional chelators, or a need for improved biochemical control.
The principal regulatory issue has been the translation of biochemical copper reduction into a clear clinical benefit-risk profile. Wilson disease is rare, heterogeneous and difficult to evaluate through conventional endpoints. Regulators may require evidence connecting copper biomarkers to neurological, hepatic or functional outcomes.
What did the Phase 3 FoCus trial evaluate?
The FoCus study was a randomized Phase 3 trial in patients with Wilson disease. It compared ALXN1840 with standard-of-care therapy and examined copper-control biomarkers over an approximately 48-week treatment period.
The main development questions were:
- Whether ALXN1840 could reduce non-ceruloplasmin-bound copper more effectively than standard treatment.
- Whether copper reduction was sustained.
- Whether the treatment was safe across hepatic and neurological disease populations.
- Whether the biomarker improvements supported clinically meaningful disease control.
ALXN1840’s commercial profile depends on more than a favorable biomarker result. Physicians and payers will assess whether the drug improves neurological symptoms, liver outcomes, treatment adherence, hospitalization risk, or long-term disease stability.
What is the FDA status of WTX101?
ALXN1840 was not an FDA-approved product in the latest publicly reported regulatory record. The absence of approval means the drug had no FDA-recognized commercial exclusivity period, no approved labeling and no Orange Book-listed patents.
A complete response letter, if issued for the application, would not necessarily terminate the program. Alexion could respond through additional analyses, labeling revisions, manufacturing remediation or further clinical work. The regulatory value of the program would depend on the specific deficiencies identified by the FDA and whether the company continued to allocate development resources.
In Europe, the regulatory pathway has also required careful assessment of clinical benefit and risk. European and U.S. outcomes may diverge because of differences in endpoint interpretation, treatment comparators and rare-disease evidence standards.
When could WTX101 lose exclusivity?
WTX101 has not entered the market, so the relevant question is the remaining term of its patent estate rather than an imminent loss of commercial exclusivity.
Patent duration generally runs 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers. For a development program originating in the early 2010s, core composition or therapeutic-use patents could extend into the early-to-mid 2030s. Later formulation, dosing and manufacturing patents could extend further, potentially into the late 2030s or early 2040s if valid and enforceable.
The actual protection period would depend on:
- The earliest priority date for each patent family
- Whether the claims cover the active compound, salt, formulation or method of use
- Patent-term adjustment
- Potential patent-term extension after approval
- Continuation and divisional applications
- Validity challenges
- The scope of any approved label
A precise expiration-date analysis requires a current family-level review of U.S., European and other national prosecution records. Public commercial information identifies the product and clinical program but does not establish a single controlling expiration date.
What patents protect ALXN1840?
The likely WTX101 patent estate has several layers:
Composition and chemical-form patents
These claims may cover bis-choline tetrathiomolybdate, specific crystalline forms, salt forms, purity levels or defined chemical compositions. Composition claims generally provide the strongest protection because they can apply across multiple indications.
Method-of-use patents
Method claims may cover treatment of Wilson disease, reduction of non-ceruloplasmin-bound copper, treatment of neurological manifestations or treatment of hepatic copper overload.
The practical value of method-of-use claims depends on the approved label and prescribing behavior. Skinny-label generic entry could avoid patented indications while still creating substitution risk if pharmacies and physicians use the product for the protected indication.
Formulation patents
Formulation claims may cover oral tablets, stability characteristics, excipients, dissolution profiles and dose regimens. Such patents can delay or complicate generic competition but are usually more vulnerable to design-around strategies than composition claims.
Manufacturing patents
Manufacturing claims may protect production of the active ingredient, control of molybdenum or copper impurities, solid-state characteristics and pharmaceutical-grade purification. These rights can raise technical barriers, but a generic manufacturer may avoid infringement by using a different process.
Does WTX101 have Orange Book protection?
No Orange Book listing would exist before FDA approval. If ALXN1840 is approved, Alexion could list patents that claim the drug substance, approved formulation or approved methods of use, subject to FDA listing rules.
The expected Orange Book structure would include:
| Potential listing category |
Relevance |
| Drug substance |
Strongest potential barrier if valid |
| Drug product |
Tablet formulation, dosage form or composition |
| Method of use |
Indication-specific protection |
| Manufacturing method |
Usually less visible in Orange Book competition |
| Pediatric exclusivity |
Possible if required studies are completed |
| Orphan-drug exclusivity |
Potential seven-year U.S. exclusivity after approval |
Orphan-drug exclusivity would be particularly important because Wilson disease qualifies as a rare disease. It would block FDA approval of the same drug for the same indication during the exclusivity period, although it would not prevent all competing therapies or necessarily block a product with clinical superiority.
What generic entry risks exist for WTX101?
Generic competition is likely to be limited in the first several years after any approval because Wilson disease is a small market and bis-choline tetrathiomolybdate may require complex bioequivalence and product-characterization work.
The main entry scenarios are:
| Scenario |
Timing after approval |
Commercial impact |
| No direct generic challenge |
0-7 years |
Maximum branded pricing power |
| Paragraph IV challenge to listed patents |
Potentially before patent expiry |
Litigation and launch uncertainty |
| Authorized generic or licensee |
Company-controlled |
Lower price, limited volume erosion |
| Competing copper therapy |
Near-term |
Pricing pressure without direct substitution |
| Generic after core patent expiry |
Approximately 10-15 years |
Significant price erosion |
A Paragraph IV certification would create an infringement dispute if Alexion sued within the statutory period. The resulting 30-month stay could delay approval of an ANDA, although the timing would depend on the listing date, certification and litigation outcome.
How strong is the patent estate for WTX101?
The patent estate is potentially moderate to strong if Alexion controls valid composition claims and secures an approved label aligned with method-of-use patents. Its strength would be weaker if protection rests mainly on narrow formulation or biomarker claims.
Key strengths include:
- Rare-disease designation and limited patient population
- Potential orphan-drug exclusivity
- Specialist prescribing
- Complex copper-biomarker management
- Limited commercial incentive for early generic entry
- Potential formulation and manufacturing barriers
Key weaknesses include:
- Possible reliance on biomarker endpoints
- Small clinical database
- The ability of competing therapies to avoid direct patent infringement
- Potential off-label substitution
- Uncertainty over the scope and duration of issued claims
- Regulatory risk if clinical benefit is not sufficiently demonstrated
How does WTX101 compare with existing Wilson disease treatments?
| Product or class |
Company or originator |
Mechanism |
Market position |
| Penicillamine |
Generic and multiple manufacturers |
Copper chelation |
Long-established, limited by tolerability |
| Trientine |
Generic; Orphalan’s Cuvrior |
Copper chelation |
Established alternative for maintenance therapy |
| Zinc salts |
Multiple manufacturers |
Reduces intestinal copper absorption |
Lower-cost, widely used |
| ALXN1840 |
Alexion |
Copper binding and removal |
Potential premium therapy if approved |
Cuvrior received FDA approval in 2022 for maintenance treatment of Wilson disease in adults and certain pediatric patients. That approval creates a direct competitive reference for ALXN1840 in the U.S. market. Penicillamine and trientine remain important because of physician familiarity, generic availability and reimbursement considerations.
ALXN1840 would need to show one or more of the following advantages:
- More rapid copper control
- Better tolerability than penicillamine
- Greater adherence through simpler dosing
- Use in patients inadequately controlled by standard therapy
- Better control of neurological or hepatic disease
- Reduced monitoring burden
- Superior patient persistence
What is the market opportunity for WTX101?
Wilson disease affects approximately one in 30,000 people globally, although prevalence varies by population and diagnosis is incomplete. A commercially relevant treated population may range from roughly 20,000 to 40,000 patients worldwide, with the United States and Europe representing the most attractive reimbursed markets.
The market projection depends heavily on annual net price and market share.
| Scenario |
Treated patients |
Annual net price |
Estimated peak sales |
| Conservative |
3,000 |
$75,000 |
$225 million |
| Base case |
5,000 |
$120,000 |
$600 million |
| Upside |
8,000 |
$150,000 |
$1.2 billion |
A more realistic base case for a premium rare-disease launch is $300 million to $800 million in annual global sales. The product would likely begin with patients who have inadequate response or intolerance to existing treatments, then expand toward earlier-line use if post-approval evidence supports broader adoption.
Revenue would be concentrated in the United States, Germany, France, the United Kingdom, Italy, Spain, Japan and selected Middle Eastern markets. Access in lower-income markets would depend on differential pricing, government procurement and patient-assistance programs.
What licensing deals affect WTX101?
The principal transaction was Alexion’s acquisition of Wilson Therapeutics in 2018. Alexion paid approximately $855 million in equity value for Wilson Therapeutics, gaining WTX101 and the associated Wilson disease development program.[1]
AstraZeneca subsequently acquired Alexion in 2021. The program is therefore controlled within AstraZeneca’s Rare Disease business. No separate commercial licensing arrangement has been central to the program’s public identity since the Wilson Therapeutics acquisition.
What patent litigation affects WTX101?
No major public Paragraph IV litigation or marketed-product patent dispute had established WTX101 as a litigation-active product before FDA approval. That position is expected because a product cannot generate ordinary Orange Book litigation until it has an approved NDA and listed patents.
If approved, likely litigation triggers would include:
- ANDA filings challenging composition patents
- Challenges to formulation patents
- Method-of-use disputes involving Wilson disease treatment
- Declaratory-judgment actions over noninfringement
- Patent-term-extension disputes
- Biosimilar litigation, which is not relevant because ALXN1840 is a small molecule rather than a biologic
What is the most likely launch scenario?
The most likely commercial scenario is a specialist rare-disease launch rather than immediate broad replacement of generic chelators.
Alexion would probably target:
- Newly diagnosed patients with high copper burden.
- Patients who fail or cannot tolerate penicillamine or trientine.
- Patients with neurological Wilson disease.
- Patients requiring more predictable copper control.
- Treatment centers with established Wilson disease expertise.
A delayed or unsuccessful regulatory outcome would reduce the program’s value sharply. Approval with a narrow label would support a smaller market, while approval supported by clinically persuasive neurological and hepatic data could justify premium pricing and earlier-line use.
Key Takeaways
- WTX101 is the former development name for ALXN1840, bis-choline tetrathiomolybdate.
- The program is owned by Alexion, part of AstraZeneca.
- The target indication is Wilson disease, a rare inherited copper-accumulation disorder.
- ALXN1840 completed Phase 3 development but was not FDA-approved in the latest publicly available regulatory record.
- No Orange Book protection or Paragraph IV litigation applies before approval.
- The most valuable potential rights are composition, method-of-use and formulation patents.
- Direct competition includes penicillamine, trientine, Cuvrior and zinc therapies.
- A reasonable peak-sales range is $300 million to $800 million, with upside above $1 billion under strong clinical differentiation.
- The main commercial risk is failure to convert biomarker improvement into a regulatory finding of meaningful clinical benefit.
- Biosimilar risk is not applicable because ALXN1840 is a small-molecule drug, not a biologic.
FAQs
Is WTX101 the same drug as ALXN1840?
Yes. WTX101 was the original development code for bis-choline tetrathiomolybdate. Alexion later used the development code ALXN1840.
Is ALXN1840 approved for Wilson disease?
No FDA approval had been established in the latest publicly available record. The product remained an investigational therapy.
Will ALXN1840 compete with Cuvrior?
Yes. Cuvrior, a trientine product, is an approved maintenance therapy for Wilson disease in the United States. ALXN1840 would compete through its copper-binding mechanism, potential tolerability advantages and possible use in patients inadequately controlled on standard therapy.
Is WTX101 a biologic eligible for biosimilar competition?
No. WTX101 is a small-molecule chemical drug. Any future competition would generally arise through generic-drug pathways rather than biosimilar approval.
What would most increase the value of the WTX101 program?
The largest value drivers would be FDA approval, a broad treatment label, evidence of neurological or hepatic benefit, durable copper control, favorable tolerability and strong patent protection extending beyond the orphan-exclusivity period.
References
-
Alexion Pharmaceuticals, Inc. (2018). Alexion to acquire Wilson Therapeutics for approximately $855 million. Company announcement.
-
AstraZeneca. (2021). AstraZeneca completes acquisition of Alexion. Company announcement.
-
ClinicalTrials.gov. (n.d.). A study of ALXN1840 in patients with Wilson disease (FoCus). U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2022). FDA approves first oral treatment for maintenance therapy in Wilson disease. FDA drug approval announcement.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
National Organization for Rare Disorders. (n.d.). Wilson disease. NORD disease information.
-
European Medicines Agency. (n.d.). Medicines for the treatment of Wilson disease. EMA regulatory and disease information.